Published January 1, 2024
| Version v1
Journal article
Open
Comparative Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review of Clinical Evidence
Authors/Creators
Description
Background: SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes mellitus (T2DM). Their effects differ across blood glucose, body weight, cardiovascular health, kidney protection and adverse events. Objective: To summarize selected published evidence from 1 January 2022 to 31 December 2024 and present a reproducible plan for a later systematic review and meta-analysis. Methods: A focused narrative assessment of verified peer-reviewed publications and clinical guidance published during 2022–2024 was undertaken. The planned formal review will use predefined eligibility criteria, duplicate screening, risk-of-bias assessment and quantitative synthesis when data permit. Findings: Available evidence supports clinically important benefits for both classes. SGLT2 inhibitors are especially relevant to heart-failure and kidney outcomes, whereas selected GLP-1 RAs provide strong glucose and weight effects and cardiovascular benefit. Safety profiles differ and require individualized choice. Conclusion: Neither drug class is best for every patient. A fully conducted head-to-head meta-analysis remains necessary for precise comparative estimates.
Files
IJSET_V12_issue6_1001.pdf
Additional details
Related works
- Has part
- Journal article: https://www.ijset.in/wp-content/uploads/IJSET_V12_issue6_1001.pdf (URL)
- Is identical to
- Journal article: https://www.ijset.in/comparative-efficacy-and-safety-of-sglt2-inhibitors-and-glp-1-receptor-agonists-in-type-2-diabetes-mellitus-a-systematic-review-of-clinical-evidence/ (URL)